WO2002041920A1 - Oral pharmaceutical compositions containing cyclodextrins as taste masking agent - Google Patents
Oral pharmaceutical compositions containing cyclodextrins as taste masking agent Download PDFInfo
- Publication number
- WO2002041920A1 WO2002041920A1 PCT/GB2001/005212 GB0105212W WO0241920A1 WO 2002041920 A1 WO2002041920 A1 WO 2002041920A1 GB 0105212 W GB0105212 W GB 0105212W WO 0241920 A1 WO0241920 A1 WO 0241920A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- active ingredient
- solid
- preparation
- oral pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- the present invention relates to the use of cyclodextrin for taste-masking in orally administered pharmaceutical compositions , to the pharmaceutical compositions themselves and to processes for making them.
- Cyclodextrins are cyclic oligosaccharides formed from ⁇ - (1,4) -linked D-glucopyranose units, ⁇ , ⁇ and ⁇ - cyclodextrins consist of six, seven and eight units respectively.
- the molecules have a toroidal shape, with a hydrophobic central cavity and a relatively hydrophilic outer surface. This structure enables cyclodextrins to bind appropriately sized non-polar guest molecules, or moieties of guest molecules, within the hydrophobic central cavity, to form clathrate complexes. Because the exterior of the cyclodextrin is relatively hydrophilic, formation of such complexes may therefore be used to increase the solubility of otherwise poorly soluble molecules-.
- cyclodextrins have been used to increase the solubility, stability and bioavailability of a variety of active drug molecules in drug formulations, and also to mask the taste of certain active ingredients, by exploiting this formation of complexes between the active ingredient and the cyclodextrin.
- bitter taste may be any of for example a bitter taste, burning taste, salty taste or other generally striging taste. It is well-known in the pharmaceutical field that some active ingredients taste so severely unpleasant that patient compliance in a tasted oral formulation is out of the question unless the taste can be masked.
- the present invention is based on the wholly unexpected finding that cyclodextrin can be effective to mask the taste of pharmaceutically active agents without the formulation of inclusion complexes between the cyclodextrin and the active agent, a step conventionally thought to be essential. This has important implications in terms of both products and production processes as regards simplicity and economy.
- the present invention provides use of a cyclodextrin to mask the taste, and particularly the unpleasant taste, of an active ingredient in a pharmaceutical preparation adapted for oral administration, wherein the active ingredient in the preparation is substantially uncomplexed by the cyclodextrin .
- a second aspect is a process of making a solid oral pharmaceutical preparation which includes blending the active ingredient - and particularly one that has an unpleasant taste - with cyclodextrin under conditions which do not promote complex formation between the cyclodextrin and active ingredient.
- a further aspect of the invention is the use, in the oral administration of a solid pharmaceutical preparation of cyclodextrin blended but not complexed with active ingredient in the preparation to mask the taste of the uncomplexed active ingredient.
- a further aspect is the use, in the preparation of a solid oral pharmaceutical preparation of the kind described, of cyclodextrin as a taste-masking agent for uncomplexed active ingredient contained in the preparation.
- the invention may have use in any situation in which it has a taste which is sought to be masked, and in particular when this is an unpleasant or very unpleasant taste.
- EP 0 839 528 A (Staroil Ltd.) dicloses use of ⁇ -cyclodextrin in mouth- soluble N-acetylcysteine compositions, in order to mask (by complexing) the taste of a sulphated degradation product of N-acetylcysteine.
- the cyclodextrin was disclosed for use to mask the taste not of the active ingredient, but of a degradation product formed during storage of the composition.
- the present proposals may not extend to preparations of kind described in which the active ingredient is N-acetylcysteine .
- the invention may be used with a wide variety of active ingredients.
- active ingredients whose taste could usefully by improved or masked include the following.
- ACE Inhibitors e.g.Benazepril, Captopril, Delapril, Enalapril, Imidapril, Ramipril: -Adrenergic Agonists e.g. Adrenolone, Clonidine, Ephedrine, Epinephrine, Phenylephrine, Fenoxazoline, Ibopamine, Methoxamine, Nafazoline, Pseudoephedrine, Tetrahydrozoline, Tramazoline, Phenyilpropanolamine, Tuaminoheptane, Tyramine Xylomethazoline ⁇ - Adrenergic Agonists ⁇ .: Albuterol,bambuterol, Clenbuterol, Clorprenaline, Dopexamine, Ephedrine, Epinephrine, Ethylnorepinephrine, F enoterolo, F ormoterolo, Isoprotereno
- Dapiprazole Fenspiride, Nicergoline, Prazosin, Yohimbine, ⁇ -Adrenergic Blockers e.g.: Acebutolol, Alprenolol, Atenolol, Befnolol, Betaxolol, Bpindolol,
- Bupranolol Carazolol, Carteolol, Celiprolol, Indenolol, Levobunolol, Mepindolol, Metipranolol, Moprolol, Pindolol, Practolol, Propranolol. Timolol; - Adrenocortical Steroids
- Adrenocorticotrop Hormones e.g. ACTH Cosintropin
- Aldose reductase inhibitors e.g. Epalrestat, Tolrestat, Zopolrestati - Aldosterone Antagonists e.g. Canrenone, Spironolattone; .
- Anabolics e.g. Androisoxazole, Androstenediol, Methandriol, Methenolon, Methiltrienolone, Nandrolone;
- Analgesics (Narcotic), e.g. Alfentanil, Buprenorphone, Codine and its derivatives, Fentanil, Meperidine, Methadone, Morphine and its derviatives Phenazocine, Propiram, Propoxiphene, Sufentanil :
- Analgesict e.g. Aceclofenac, Acetaminophen, Acetysalicyic acid, Alclofenac, Alminoprofen, Antypirine, Benorilate, Benoxoprofen, Bromfenac, Bucetin, Carbamazepine, Carbiphene, Chlortenoxazin, Cholin salicyate, Clometacin, Clonixin, Croropamide, Diflunisal, Etodolac, Felbinac, Fenoprofen, Flufenamiv acid, Flurbiprofen, Ibufenac, Imidazole salicylate, Indomethacin, Indoprofen, Ketoprofen, Ketorolac, Mofezolac, Naproxen, Nifenazone, Phenacetin, Propyphenazone, Sutrofen, Tenoxicam, Terofenamate, Tolfenamic acid, Tramadol, Vi
- Androgens e.g. Boldenone, Cloxotestosterone, Mestanolone, Mesterolone, Methandrostenolone, Norethandrolone, Normethandrone, Oxandrolone, Oxymesterone, Oxymetholone, Prasterone, Stanolone, Stanozolol, Testosterone,
- Angiotensin II receptor antagonists e . g.Candesartan, Eprosartan, Ibesartan, Losartan, Valsartan:
- Anorexics e.g. Aminorex, Amphecloral, Anphetamine, Benzphetamine, Chlorphentermine, Clobenzorex, Clortermine, F enfluramine, Norpseudoephedrine, Pentorex, Phendimetrazine, Phenmetrazine;
- Anthelmintics e.g. Arecoline, Aspidin, Aspidinol, Becanthone, Hycantone, .
- Antiallergics e.g. Amlexanox, stemizole, Azelastine, Cromolyn, Fempiprane, Ibudilast, Lodoxamide,
- Antialopecia agent e.g. Cioteronel, Minoxidil
- Antiamebics e.g.Arsthinol, Carbasone, Chlorbetamide,
- Verapamil - Antiarrhythmics e.g. Acebutol, Adenosine, Aj aline, Alprenolol, Amiodarone, Atenolol, Bupranolol, Carazolol, Carteolol, Cloranolol, Indenolol, Ipratropium bromide, Lidocaine, Pindolol, Propafenone, Propranoll, Quinidine, Timolol, Verapamil;
- Antiarteriosclerotic e.g. Pyridinol Carbamate
- Antiarthritics/Antirheumatics e.g. Actarit, Auranofin.
- Antiasthmatics e.g. Azelastine, Cromolyn, Ibudilast, Ketotifen, Montelukast, Oxotomide, Pranlukast, Seratrodast, Zafirlukast, Zileuton, Beclomethasone, Budesonide, Dexamethasone, Flunisolide, Triamcinolon acetonide.
- Antibacterials e.g. Amikacin, Gentamicin, KanamycinNeomicin, Tobramycin, Chloramphenicol, Thiamphenicol, Rifamide, Rifampin, Rifaximin, Cefaclor, Cefamandole Cefazolin, Cefiime, Cefazolin, Amoxicillin, Ampicillin, Oxacillin, Lindomycin, Erythromycin, Gramicidin, Teicoplanin, Vancomycin, Chlortetracycline Doxycylline, Tetracycline, Trimetoprim, Nifuradene, Nitrofurantoin, Ciprofloxacin, Ofloxacin, Lomefloxacin, Benzylsulamide, Chloraminet, Mafenide, Sulfabenzamide, Sulfacetamide, Sulfadiazine, Sulfadoxine, Sulfaguanidine, Sulfalene, Sulfanilamide, Sulfanylurea, sul
- Anticholinergics e.g. Atropine, Fentomum bromide, Homatropine, Hyoscyamine, Ipratropium bromide, Isopropramide iodide, Scopola ine, Tropicamide:
- Anticoagulants e.g. Acecumarol, Bromindione, Clorindione, Coumetarol, Dicumarol, Diphenadione, Fluindione, Heparin, Hirundin, Phenindione, Warfarin;
- Anticonvulsants e.g. Albutoin, Aloxidone, Aminoglutethimide, Beclamide, Carbamazepine, Clonazepam, Ethadine, Ethotoin, Felbamate, Mephenytoin, Narcobarbital, Nimethazepam, Nitrazepam, Paramethadione, Phenacemide, Phenobarbital, Phenitoin, etc..
- Antidepressant i.e.: Citalopram, Fencaine, Nefopam, Iproclozide, Isocarboxazid, Nialamide, Rolyciprine, Maprotiline, Metralindole, Amytriptiline, Clomipramide, Desipramide, Dibenzepin, Imipramide, Trimipramide, Bupropion, etc..
- Antidiabetic i.e.: Buformin, Phenformin, Insulin, Carbutamide, Chlorpopamide, Glipizide, Phenbutamide, Tolazamide, Tolbutamide, Tolcyclamide etc.
- Antidiarreal i.e. : Acetorphan, Catechin, Difenoxin, Diphenoxylate, Loperamide, Mebiquine, etc
- Antidiuretic i.e.: Desmopressin, Felypressin, Ornipressin, Vasopressin, etc..
- Antidote i.e.: Acetylcysteine, Cysteamine, Methionine, Folinic Acid, etc..
- Antidyskinetic i.e.: Amantidine, Clonidine, Haloperidol, Pimozide, Tetrabenazine etc..
- Antiemetic i.e. : Alizapride, Azasentron, Benzquinamide, Bromopride, Buclizine, Chlorpromazine, Cyclizine, Domperidone, Granisetron, Meclizine, Metoclopra ide, Ondansentron,
- Antiglaucoma i.e.: Acetozolamide, Betaxolol, Bupranolol, etc..
- Antigout i.e.: Allopurinol, Colchicine, Probenecid, Sulfipyrazone, etc.
- Anthistaminic i.e.: Acrivastine, Brompheniramine, Chlorpheniramine, Dimethindene, Pheniramine, Tolpropamine, Clemastine, Diphenidramine, Medrilamyne, Cetirizine, Chlorcyclizine, Cinnarizine, Hidroxyzine, Fenethazine, Promethazine, Loratadine, Antazoline, Astemizole, Azelastine, Ebastine, Fexofenadine, Terfenadine, etc..
- Anthyperlipoproteinemic i.e.. Cholestiramine, Benzofibrate, Clofibrate, Etofibrate, Genfibrozil, Atorvastatin, Lovastatin, Niceritrol, Thyroxine,
- Anthypertensive i.e.: Bufuralol, Acebutolol, Atenolol, Carteolol, Metoprolol, Moprolol, Pindolol, Propranolol, Timolol, Chlorthiazide, Cyclopenthiazide, Hydroflumethazide, Benazepril, Captopril, Lisinopril, Ra ipril, Air ⁇ Lodipine,
- Felodipine Lacidipine, Nicardipine, Nitrendipine, Bethnide, Budralazine, Hydralazine; Pheniprazine, Phentolamine, Bunazosin, Prazosin, Reserpine, Furosemide, Ajmaline, Fenoldopam, Mebutamate, Methildopa, Minoxidil, etc..
- Antihypotensive i.e.: Dopamine, Etilefrin, Norepinephrine, Synephrine, etc..
- Flufenamic Acid Mecoflenamic Acid, Tolfenamic Acid, Aceclofenac, Alclofenac, Bromfenac, Diclofenac Sodium, Etodolac, Ibufenac, Indomethacin, Pirazolac, Sulindac, Tolmetin, Fenbufen, Ketorolac, Alminoprof n, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Feprazone, Benorylate, Piroxicam, Bendazac, Nimesulide, etc.
- Antimalarial i.e.; chloroquine, Chlorproquanil, Cinchonide, Cycloguanil, Quinidine, etc..
- Antimigraine i.e. : Dolasetron, Ergocornine, Ergocriptyne, Ergot, Ergotamine, Lomerizine, Sumatriptan, etc..
- Antiparkinsonian i.e.: Amantadine, Bromocriptine, Carbidopa, Levodopa, etc..
- Antipsychotic i.e. : Alizapride, Amilsulpiride, Sulpiride, Risperidone, Haloperidol, Acetophenazine, Chlorpromazine, Fluphenazine, Perazine, etc..
- Antipyretic i.e.: Acetaminophen, Alclofenac, Aspirin, Benorilate, Indomethacin, etc..
- Antispasmodic i.e.: Aminopromazine, Fentonium Bromide, Rociverine, Tiropramide, etc..
- Antitussive ie.: Cloperastine, Codeine and derivetives, Dextromethorphan. Morclofone, etc..
- Antiulcerative i.e.: Acetoxolone, Cimetidine,
- Famotidine Omeprazole, Pirenzepine, Ranitidine, Sucralfate, etc.
- Anxiolytic i.e.: Buspirone, Alprazolam, Broazepam, Camazepam, Lorazepam, Nordazepam, Meprobamate, etc..
- Bronchodilator i.e. : Albuterol, Bambuterol, Calbiterol, Clenbuterol, Clorprenaline, Ephedrine,
- Ephineprine Folmoterol, Metaproterenol, Salmeterol, Terbutaline, Ipratroprium Bromide, Teophilline and derivatives, etc..
- - Calcium channel blocker i.e. : Diltiazem, Verapamil, Amlodipine, Lacidipine, Micardipine, Nifedipine, Nomerizine, etc..
- Cardiotonic i.e.: Digitalin, Digitoxin, Digoxin, Dopamine, Uabain, Scillaren, etc..
- Choleretic i.e. : Cholic Acid, Cynerin, Dehydrocholic Acid, Dehoxycolic Acid, Taurocolic Acid, etc..
- Cholinergic i.e.: Acetylcholine, Benzepirinium Bromide, Carbachol, Neostigmine, Physostigmine, etc.. - CNS stimolant i.e.: Amphetamine, Caffeine, Fenozolone, Phentermine, etc..
- Diuretic ie Bendroflumethiazide, Benzylhytrochlorothiazide, Chlorothiazide, Indapamide, Mersalil, Candrenone, Oleandrin, Spironolattone, Acetazolamide, Butazolamide, Clopramide, Furosemide, Isosorbide, etc..
- Dopamine receptor agonist i.e.: Bromocriptine, Cabercoline, Dopexamine, Fenoldopam, etc..
- Dopamine receptor antagonist i.e. : Amisulpride, Domperidone, Metoclopamide, Sulpiride, etc..
- Enzyme i.e.: Amylase, Lysozyme, Papain, etc..
- Expetorant i.e.: Ambroxol, Bromhexine, Carbocysteine, Guaiacol, Guaifenesin, etc..
- Gastric and Pancreatic secretion stimulant i.e.: Carnitine Ceruletide etc..
- Gastric proton pump inhibitor i.e.: Lansoprazole, Omeprazole, Pantoprazole, etc.
- Gastric secretion inhibitor i.e.: Enterogastrone, Octretide, Telenzepine, etc..
- Gastroprokinetic i.e.: Cinitapride, Cisapride, Fenotozine, Loxiglumide, etc..
- Glucocorticoid i.e. : Beclomethasone, Bethometasone, Budesonide, Chloroprednisone, Clobetasone, Cortisone, Corticosterone, Deflazacort, Dexamethasone, Flumethasone, Fluocinolone Acetonide, Fluazacort, Fuorometholone, Flunisolide, Fluprednisolone, Hydrocortisone, Methylprednisolone, Prednisolone, Prednisone, Tria cinolone etc.. - Hemolytie, i.e.: Phenilhydrazine etc..
- Histamine H 2 -receptor antagonist i.e.: Cimetidine, Ebrotidine, Famotidine, Nizatidine, Ranitidine, etc..
- Laxative/Cathartic i.e.: Frangulin, Phenolphtaleine, Picosulfate sodium, etc..
- - Leukotriene antagonist i.e.: Ibudilast, Montelukast, Pranlukast, Zafirlukast etc..
- - Mucolitic i.e.: Acetylcysteine, Bromexine, Carbocysteine, Lysozime, Sobrerol, Tyloxapol, etc..
- - Muscle relaxant i.e. : Afloqualone, Baclofen, Curare, Cyclarbamate, Dandrolene bromide, Diazepam, Eperisone, Flumetramide, Mephenesin Mephenaxolone, Methaxolone, Methocarbamol, Nimethazepam, Succyinylcholine Bromide Tetrazepam, Tubocurarine, etc.
- Narcotic Antagonist i.e.: Amiphenazole, Naloxone, Naltaxone etc..
- Nootropic i.e.: Aceglutamide, Besipiride, Piracetam, Vinconate, etc..
- Oxytocic i.e.: Carboprost, Deaminooxytocic, Ergonovine, Gemeprost, Methylergonovine, Oxytocin, Prostaglandin E 2 , Prostaglandin F 2a etc..
- Progestogen i.e. : Drospirenone, Dydrogesterone, Ethynodiol, Flurogestone acetato, Lynestrenol, Medrogestone, Medroxyprogesterone, Megestrol acetato Norgesterone, Pentagestrone, Progesterone, etc..
- - Prolactin hinhibitor i.e.: i.e: Bromocriptine, Cabergoline, Lisuride, Metergoline, Quinagoline, etc..
- Prostaglandin/ Prostaglandin analog i.e.: Beraprost, Carboprost, Enprostil, Gemeprost, Limaprost, Misoprostol, Prostacyclin, Prostaglandin E ⁇ ,E 2 , F 2a etc..
- Respiratory stimulant i.e. : Almitrine, Bemegride, Cropropa ide, Dimorpholamine, Lobeline, Pyridopylline, etc. .
- Retroviral transcriptase inhibitor i.e.: Delavirdine, Didanosine, Dideoxyadenosine, Lamivudine, Stavudine, Zidovudine - Sedative/Hypnotic, i.e: Accarbromal, Butoctamide, Di ethylbromoactamide, Niaprazine, Trimetozine, Zolpidem, Zopiclone, Allobarbital, Amobarbital, Barbital, Cyclopentobarbital, Hexobarbital, Mephobarbital, Narcobarbital, Pentobarbital, Phenobarbital, Tetrabarbital, Estazolam, Flunitrazepam, Flurazepam, Loprazolam, Lorttletazepam, Nitrazepam, Piperidione, Acetophenone, Clomethiazole Doxylamine, Te azepam, Triazolam, Methaqualone, Gluteth
- Serotonin Noradrenaline reuptake inhibitor i.e, Duloxetine, Velanfaxine, etc .
- - Serotonin reuptake agonist i.e.: Buspirone, Eltoprazine, Ergotamine, Sumatriptan etc..
- Serotonin receptor antagonist i.e.: Azasentron, Dolasentron, Granisentron, Ondasentron, Ritanserin, Tropisentron, etc.
- Serotonin uptake inhibitor i.e.: Fomexitine, Fluoxetine, Paroxetine etc..
- Vasodilator i.e.: Cinnarizine, Citicoline, Fenoxedil, Flunarizine, Lomerizine, Nicergoline, Nimodipine, Papaverine, Amotriphene, Vincamine, Efloxate, Nitroglicerin, Pentrinitrol, Trapidil Bradykinin, Inositol, Nicergoline, Pentifillyne, Tlazoline, etc. .
- Vitamins i.e.: Calcitriol, Ergosterol, Vitamin D, D , D 3 , Ascorbic acid, ⁇ -Carotene, vitamin B ⁇ 2 etc..
- the solid pharmaceutical preparations of the present inventions may take various forms . They may be buccal tablets adapted to dissolve in the mouth. Such tablets may be placed in the buccal cavity, on the tongue or between the cheek and gums, for dissolution over a period depending on the chosen excipients .
- One preferred embodiment is a fast-melting buccal tablets made from a fluidised-bed granulated blend containing polyalcohol such as is disclosed in our WO-A-99/04758.
- sublingual tablets which are adapted to be placed under the tongue where the active ingredient can be absorbed directly into the blood stream through the mucosa.
- a further embodiment is a chewable tablet. Techniques and materials for making chewable tablets are well known.
- a further embodiment is a preparation adapted to be dissolved or dispersed in a carrier such as water for ingestion.
- a carrier such as water for ingestion.
- suitable excipients for these purposes are well known and it may be necessary only to include the necessary cyclodextrin in the preparation.
- effervescent agents such as bicarbonates may be included in the formulation.
- the preparation may be in the form of tablets, granules or powder.
- the cyclodextrin for use according to the present invention may be an ⁇ , ⁇ , or ⁇ -cyclodextrin.
- cyclodextrin derivatives such as hydroxypropyl- ⁇ - cyclodextrin, and acylated and modified cyclodextrins, for example those described in US Patents 5,654,422 and 5,633,368 (both to Hirsenkorn) and WO91/13100 (Australian Commercial Research and Development Ltd.), are also available for use in the invention.
- the cyclodextrin is a ⁇ -cyclodextrin or derivative thereof.
- compositions according to the present invention may be prepared by any suitable method which creates a homogeneous mixture of active ingredient and cyclodextrin without requiring any particular processes conditions to generate complexes between active and cyclodextrin.
- Mixtures may be prepared by simple dry blending, or by blending with a small quantity of water or other solvent to facilitate homogenisation.
- Actives may be granulated with cyclodextrin using a fluid bed granulator (preferred) or a granulating blender, using sufficient water or other suitable solvent to achieve a satisfactory granulation, but generally without such quantities of water as might give rise to significant complex formulation, e.g. by converting the mix to a paste or slurry.
- compositions may also be blended or granulated into the active-cyclodextrin mixture.
- the nature of these excipients will depend upon the required final form of the pharmaceutical.
- polyalcohol such as any one or more of xylitol, sorbitol, mannitol, maltitol, erythritol and lactitol may be included.
- the preparation may contain an ingestible acid component, e.g. citric acid, typically up to 30wt% of the total.
- an ingestible acid component e.g. citric acid
- the preparations may contain effervescence agent selected from various acid and/or base components.
- Suitable acids include citric, tartaric, malic, fumaric, adipic, succinic and alginic acids. Acid salts and anhydrides may also be used.
- Suitable bases include solid carbonates and bicarbonates .
- the preparation contains not more than about 10wt% of effervescent agent, but this may be varied in accordance with known practice.
- the pharmaceutical compositions of the present invention may contain a single active ingredient or a plurality of active ingredients . Where more than one active ingredient has a taste which is required to be masked, the quantity of cyclodextrin can be adjusted appropriately .
- Satisfactory taste masking can typically be achieved using a molar ratio of active or actives to cyclodextrin of between 0.9:1 and 1:25, preferably between 1:1 and 1:15.
- Magnesium stearate 5g Vanilla flavour 24g This mixture was blended for 15 minutes to reach homogeneity, and the resulting mixture compressed on a rotating tabletting machine, with a toroidal punch of 13mm diameter, to give tablets weighing 800mg each.
- the resulting tablets showed good mechanical characteristics and had a pleasant taste when dissolved in the buccal cavity.
- Example 1 was repeated omitting the cyclodextrin and adjusting the total weight to 500mg to achieve the same active dose.
- the tablets had good mechanical and dissolution characteristics but a very unpleasant strong bitter taste in the mouth.
- the mixture was blended for 15 minutes to reach homogeneity, and the resulting mixture compressed on a rotating tabletting machine with a toroidal punch of 13mm diameter, to give tablets weighing 800mg each.
- the resulting tablets showed good mechanical characteristics and pleasant taste when dissolved in the buccal cavity.
- Comparison 2 Example 2 was repeated omitting the cyclodextrin, adjusting the tablet weight to 500g to achieve the same active dose. Although good in mechanical and dissolution properties, the tablets had a very unpleasant bitter taste I the mouth.
- Chewable tablets each containing lOmg Dextromethorphan HBr, 2mg Chlorpheniramine maleate and 6.67mg Lysozyme HCl were prepared as follows .
- Citric acid lOg were granulated together with just sufficient water, for granulation, containing lOg PVP K 25. To the dried granulate was added
- the mixture was blended for 15 minutes to reach homogeneity, and the resulting mixture compressed on a rotating tabletting machine with a toroidal punch of 16mm diameter, to give tablets weighing llOOmg each.
- the resulting tablets showed good mechanical characteristics and had a pleasant taste when chewed.
- Example 3 was repeated omitting the cyclodextrin and adjusting the tablet weight to 750mg to maintain the dose of active ingredients .
- the tablet had a very unpleasant strong bitter taste when chewed.
- Example 4 Effervescent tablets each containing lOmg
- Dextromethorphan HBr 2mg Chlorpheniramine maleate and 6.67mg lysozyme HCl were prepared as follows:
- Citric acid 1400g were granulated with just sufficient water for granulation, containing 18g of ⁇ -carotene. To the resultant dry granulate was added
- the mixture was dried for 20 minutes, and compressed on a rotating tabletting machine with a toroidal punch of 22mm diameter, to give tablets weighing 3500mg each.
- the resulting tablets showed good mechanical characteristics and pleasant taste when dissolved in water and drunk.
- Example 4 was repeated omitting the cyclodextrin and adjusting the tablet size to achieve the same dose. The tablets dissolved well but the solution had an unpleasant bitter taste.
- the mixture was blended for 15 minutes to reach homogeneity, and compressed on a rotating tabletting machine with a toroidal punch of 13mm diameter, to . give tablets weighing 1200mg each.
- the resulting tablets showed good mechanical characteristics and pleasant taste when dissolved in the buccal cavity.
- Example 5 was repeated omitting the cyclodextrin and adjusting tablet size to lOOlmg to maintain the dose.
- the resulting tablets had good mechanical properties but an unpleasant bitter taste when dissolved in the mouth.
- Water soluble granulate was prepared as follows . Ibuprofen 200g
- the mixture was blended for 15 minutes to reach homogeneity, and divided into 4000mg doses packaged into aluminium paper sachets containing 200mg ibuprofen each.
- the resultant granulates had a pleasant taste when dissolved in water and drunk.
- Example 6 was repeated omitting the cyclodextrin and reducing sachet contents to 3000mg to maintain dose size.
- the dissolved granules had an unpleasant burning and irritating taste.
- Water soluble granulates containing 50mg ketoprofen per dose were prepared as follows.
- the resultant mixture was divided 5 into 2000mg doses packaged into aluminium paper sachets.
- the resultant granulates had a pleasant taste when dispersed in water and drunk.
- Example 7 When the cyclodextrin was omitted from the Example 7 preparation the dispersed granulates had an unpleasant irritating and burning taste.
- Water soluble granulates containing 70mg sumatriptan per dose were prepared as follows.
- Example 8 was repeated omitting the cyclodextrin, reducing the dose to 1155g to maintain the active dose. Dispersed in water, the granulate had an unpleasant bitter taste.
- the mixture was blended for 15 minutes to reach homogeneity, and compressed on a rotating tabletting machine with a toroidal punch of 8mm diameter, to give tablets weighing 120mg each.
- Example 9 When Example 9 was repeated without the cyclodextrin, reducing the tablet weight to 99mg to maintain the active content, the resulting tablet had good mechanical properties but an unpleasant and very bitter taste when dissolved in the mouth.
- the mixture was blended for 15 minutes to reach homogeneity, and compressed on a rotating tabletting machine with a toroidal punch of 8mm diameter, to give tablets weighing 1200mg each .
- the resulting tablets showed good mechanical characteristics, and a pleasant taste when dissolved in the buccal cavity.
- Example 10 was repeated omitting the cyclodextrin and with the tablets at 825mg to give the same active dose.
- the resulting tablets had good mechanical properties but an unpleasant and persistent bitter taste when dissolved in the mouth.
- the mixture was blended for 15 minutes to homogeneity and compressed to 1385mg tablets on a rotating tableting machine using a 16mm-diameter toroidal punch.
- the tablets had good mechanical properties, and a pleasant taste when dissolved in the buccal cavity.
- Example 11 was repeated omitting the cyclodextrin, and producing 842mg tablets (with a 13mm punch) to achieve the same lOOmg dose of aceclofenac.
- the resulting tablets had good mechanical properties but an unpleasant and persistent bitter taste when dissolved in -the buccal cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01997315A EP1347781A1 (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent |
CA2429650A CA2429650C (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent |
AU2002220825A AU2002220825A1 (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent |
JP2002544097A JP2004517825A (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical composition containing cyclodextrin as taste masking agent |
US10/432,575 US20040115258A1 (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0028575.9 | 2000-11-23 | ||
GBGB0028575.9A GB0028575D0 (en) | 2000-11-23 | 2000-11-23 | Oral pharmaceutical compositions containing cyclodextrins |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002041920A1 true WO2002041920A1 (en) | 2002-05-30 |
Family
ID=9903730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/005212 WO2002041920A1 (en) | 2000-11-23 | 2001-11-23 | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040115258A1 (en) |
EP (1) | EP1347781A1 (en) |
JP (1) | JP2004517825A (en) |
AU (1) | AU2002220825A1 (en) |
CA (1) | CA2429650C (en) |
GB (1) | GB0028575D0 (en) |
WO (1) | WO2002041920A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008013710A2 (en) | 2006-07-25 | 2008-01-31 | Wyeth | Chewable tablet containing phenylephrine |
US20090035375A1 (en) * | 2004-04-22 | 2009-02-05 | Stanko Skrtic | Pharmaceutical compositions for acute glucocorticoid therapy |
WO2009023434A2 (en) * | 2007-08-13 | 2009-02-19 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
AU2003249268B2 (en) * | 2002-07-25 | 2009-05-28 | Colgate-Palmolive Company | Oral composition providing enhanced oral hygiene properties |
US8613948B2 (en) | 2001-12-21 | 2013-12-24 | Norgine Bv | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine |
WO2014148883A1 (en) * | 2013-03-20 | 2014-09-25 | Natureceuticals Sdn Bhd | Herbaceutical formulations |
EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11267818B2 (en) | 2008-10-22 | 2022-03-08 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1011251A3 (en) * | 1997-07-03 | 1999-06-01 | Ucb Sa | Pharmaceutical administrable oral, including an active substance and cyclodextrin. |
EP1563848A1 (en) * | 2004-02-12 | 2005-08-17 | Bioprojet | New combinations of an anti-emetic agent and an enkephalinase inhibitor |
ATE464883T1 (en) * | 2004-07-22 | 2010-05-15 | Bend Res Inc | FLAVOR-COVERING FORMULATION WITH A RETARDED-RELEASE INGREDIENT FORMULATION AND/OR QUICKLY SOLUBLE CYCLODEXTRIN |
KR100672184B1 (en) * | 2004-09-21 | 2007-01-19 | 주식회사종근당 | Paroxetine cholate or cholic acid derivative salts |
KR100957731B1 (en) * | 2005-04-11 | 2010-05-12 | 오노 야꾸힝 고교 가부시키가이샤 | Pranlukast hydrate-containing preparation having relieved bitterness |
PL2656860T3 (en) * | 2005-06-17 | 2021-11-08 | Wisconsin Alumni Research Foundation | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
US8715731B2 (en) * | 2006-03-22 | 2014-05-06 | Isp Investments Inc. | Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin |
FR2900823B1 (en) * | 2006-05-15 | 2009-02-13 | Bioprojet Soc Civ Ile | NEW FORM OF ADMINISTRATION OF RACECADOTRIL. |
CA2617688C (en) * | 2007-02-22 | 2015-08-18 | Alpex Pharma S.A. | Solid dosage formulations containing weight-loss drugs |
ITMI20071971A1 (en) * | 2007-10-10 | 2009-04-11 | Altergon Sa | PHARMACEUTICAL COMPOSITION FOR SUBLINGUAL ADMINISTRATION OF PROGESTERONE, AND METHOD FOR ITS PREPARATION |
US20100120776A1 (en) * | 2008-11-12 | 2010-05-13 | Hall Bioscience Corporation | Carbocysteine medical foods |
CN102448499A (en) * | 2009-04-27 | 2012-05-09 | 药效学应用实验室股份有限公司 | Oral ibuprofen lysinate suspension |
PL3679941T3 (en) | 2009-06-18 | 2023-04-17 | Serenity Pharmaceuticals Llc | Safe desmopressin administration |
JP5552400B2 (en) * | 2010-09-07 | 2014-07-16 | 東亜薬品株式会社 | Granules masking bitterness and unpleasant taste of herbal medicines and intraoral quick disintegrating tablets |
US20140213644A1 (en) * | 2010-12-30 | 2014-07-31 | Ziv Harish | Formulations and Methods for Prevention and Treatment of Oral Allergy Syndrome |
CN103381272A (en) * | 2012-05-03 | 2013-11-06 | 贵州大学 | Method for improving levodropropizine taste by cyclodextrin clathration |
US9114171B2 (en) * | 2012-06-28 | 2015-08-25 | Mcneil-Ppc, Inc. | Racecadotril liquid compositions |
JP6282644B2 (en) * | 2012-06-28 | 2018-02-21 | ジヨンソン・アンド・ジヨンソン・コンシユーマー・インコーポレーテツドJohnson & Johnson Consumer Inc. | Racecadotril liquid composition |
WO2014152207A1 (en) * | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
KR101555908B1 (en) * | 2013-12-19 | 2015-09-25 | 한미약품 주식회사 | Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing the same |
EP3434114A1 (en) * | 2017-07-27 | 2019-01-30 | Interquim, S.A. | Sweetening and taste-masking compositions |
JP2020019731A (en) * | 2018-07-31 | 2020-02-06 | 日本食品化工株式会社 | Bitter taste inhibitor of amlodipine besilate |
US10952981B2 (en) * | 2019-05-27 | 2021-03-23 | Slayback Pharma Llc | Liquid pharmaceutical compositions of baclofen for oral administration |
JP2021147362A (en) * | 2020-03-23 | 2021-09-27 | 学校法人常翔学園 | Jelly agent for sublingual administration |
CN114569742B (en) * | 2022-05-09 | 2022-07-19 | 北京剂泰医药科技有限公司 | Composition and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63243031A (en) * | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | Solid pharmaceutical of bile acid |
EP0468392A1 (en) * | 1990-07-27 | 1992-01-29 | Jagotec Ag | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained |
EP0839528A1 (en) * | 1996-10-29 | 1998-05-06 | Staroil Limited | Mouth-soluble compositions containing N-acetylcysteine and cyclodextrin |
WO1999001133A1 (en) * | 1997-07-03 | 1999-01-14 | Ucb, S.A. | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
EP1129709A2 (en) * | 2000-03-03 | 2001-09-05 | Laboratorio de Aplicaciones Farmacodinamicas, S.A. | Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206025A (en) * | 1989-05-24 | 1993-04-27 | Rhone-Poulenc Sante | Porous pharmaceutical form and its preparation |
US5290569A (en) * | 1990-04-12 | 1994-03-01 | Shionogi & Co., Ltd. | Coated composition and its preparation process |
US6525214B1 (en) * | 1991-05-13 | 2003-02-25 | Bernard John Armitage | Therapeutic agent |
DE4414128A1 (en) * | 1994-04-22 | 1995-10-26 | Consortium Elektrochem Ind | Partially acylated beta-cyclodextrins |
DE4414138A1 (en) * | 1994-04-22 | 1995-10-26 | Consortium Elektrochem Ind | Acylated gamma cyclodextrins |
-
2000
- 2000-11-23 GB GBGB0028575.9A patent/GB0028575D0/en not_active Ceased
-
2001
- 2001-11-23 AU AU2002220825A patent/AU2002220825A1/en not_active Abandoned
- 2001-11-23 JP JP2002544097A patent/JP2004517825A/en active Pending
- 2001-11-23 EP EP01997315A patent/EP1347781A1/en not_active Ceased
- 2001-11-23 WO PCT/GB2001/005212 patent/WO2002041920A1/en not_active Application Discontinuation
- 2001-11-23 US US10/432,575 patent/US20040115258A1/en not_active Abandoned
- 2001-11-23 CA CA2429650A patent/CA2429650C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63243031A (en) * | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | Solid pharmaceutical of bile acid |
EP0468392A1 (en) * | 1990-07-27 | 1992-01-29 | Jagotec Ag | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained |
EP0839528A1 (en) * | 1996-10-29 | 1998-05-06 | Staroil Limited | Mouth-soluble compositions containing N-acetylcysteine and cyclodextrin |
WO1999001133A1 (en) * | 1997-07-03 | 1999-01-14 | Ucb, S.A. | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
EP1129709A2 (en) * | 2000-03-03 | 2001-09-05 | Laboratorio de Aplicaciones Farmacodinamicas, S.A. | Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 013, no. 049 (C - 565) 3 February 1989 (1989-02-03) * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8613948B2 (en) | 2001-12-21 | 2013-12-24 | Norgine Bv | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine |
AU2003249268B2 (en) * | 2002-07-25 | 2009-05-28 | Colgate-Palmolive Company | Oral composition providing enhanced oral hygiene properties |
US7601338B2 (en) | 2002-07-25 | 2009-10-13 | Colgate-Palmolive Co. | Antiplaque oral composition containing enzymes and cyclodextrins |
EP1551361B1 (en) * | 2002-07-25 | 2010-09-01 | Colgate-Palmolive Company | Oral composition providing enhanced oral hygiene properties |
US20090035375A1 (en) * | 2004-04-22 | 2009-02-05 | Stanko Skrtic | Pharmaceutical compositions for acute glucocorticoid therapy |
US9925139B2 (en) * | 2004-04-22 | 2018-03-27 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
WO2008013710A2 (en) | 2006-07-25 | 2008-01-31 | Wyeth | Chewable tablet containing phenylephrine |
WO2008013710A3 (en) * | 2006-07-25 | 2008-07-24 | Wyeth Corp | Chewable tablet containing phenylephrine |
US9005652B2 (en) | 2006-07-25 | 2015-04-14 | Wyeth | Chewable tablet containing phenylephrine |
AU2008287177B2 (en) * | 2007-08-13 | 2013-03-28 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
EP2246045A1 (en) * | 2007-08-13 | 2010-11-03 | McNeil-PPC, Inc. | Method for stabilizing phenylephrine |
WO2009023434A3 (en) * | 2007-08-13 | 2009-04-09 | Mcneil Ppc Inc | Method for stabilizing phenylephrine |
WO2009023434A2 (en) * | 2007-08-13 | 2009-02-19 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
US11267818B2 (en) | 2008-10-22 | 2022-03-08 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
WO2014148883A1 (en) * | 2013-03-20 | 2014-09-25 | Natureceuticals Sdn Bhd | Herbaceutical formulations |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
WO2021014275A1 (en) | 2019-07-19 | 2021-01-28 | Biopharma Synergies, S.L. | Orodispersible powder composition comprising a triptan |
EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
Also Published As
Publication number | Publication date |
---|---|
JP2004517825A (en) | 2004-06-17 |
CA2429650A1 (en) | 2002-05-30 |
CA2429650C (en) | 2010-09-07 |
EP1347781A1 (en) | 2003-10-01 |
US20040115258A1 (en) | 2004-06-17 |
GB0028575D0 (en) | 2001-01-10 |
AU2002220825A1 (en) | 2002-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2429650C (en) | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent | |
EP2254558B1 (en) | Orally disintegrating tablets with speckled appearance | |
ES2870142T3 (en) | Oral administration vehicle | |
ES2260961T3 (en) | CONSUMABLE FILMS BY QUICK DISSOLUTION ORAL VIA. | |
ES2586611T3 (en) | Oral formulations of controlled / modified release methylphenidate | |
ES2342090T3 (en) | PHARMACEUTICAL FORMULATIONS OF OPENING AGENTS OF POTASSIUM CHANNELS DEPENDENT ON ATP AND USES OF THE SAME. | |
JP4145048B2 (en) | Rapidly soluble and orally exhaustible film containing an ion exchange resin as a taste masking agent | |
ES2316550T5 (en) | Degradable chewing gum coated with an improved shelf life and preparation procedure | |
ES2860802T3 (en) | Tablet comprising a separate binder and erythritol | |
ES2792082T3 (en) | Enhanced Stability of Novel Liquid Compositions | |
ES2319191T3 (en) | COMPRESSED MASK RUBBER PAD. | |
CA2512988C (en) | Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same | |
ES2354688T3 (en) | FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE COMPOUNDS. | |
BRPI0906648A2 (en) | edible film strips for immediate release of active ingredients | |
EP2004146B1 (en) | A tablet of paracetamol containing an encapsulated flavorant | |
ES2309347T3 (en) | COMPRESSED CHICLE OF MODERATE RESIN. | |
JP2009501752A (en) | A rapidly disintegrating oral disintegrating film for neuroleptics | |
ES2351969T3 (en) | COMPRESSED BIODEGRADABLE CHICLE. | |
EP1077684B1 (en) | Effervescent preparations | |
EA012081B1 (en) | A pharmaceutical composition comprising gabapentin | |
ES2301797T3 (en) | NON BENZODIAZEPINIC SEDANTES FORMULATIONS. | |
Joshi et al. | Review on mouth dissolving tablet | |
Sharma | Fast Disintegrating Tablets: A Review On An Emerging Trend In Novel Oral Drug Delivery Technology And New Market Opportunities | |
Ganaie et al. | Formulation development and evaluation of mucoadhesive buccal film of methyldopa | |
RU2001116585A (en) | Controlled release of active agents from chewing gum coating |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002544097 Country of ref document: JP Ref document number: 2429650 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001997315 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001997315 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432575 Country of ref document: US |
|
WWR | Wipo information: refused in national office |
Ref document number: 2001997315 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001997315 Country of ref document: EP |